Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Outpatient women meeting Diagnostic and Statistical Manual of Mental Disorders Manual, Fourth Edition, Text Revision (DSM-IV TR) criteria for a single or recurrent, non-psychotic episode of Major Depressive Disorder (296.2x and 296.3x).

• Patients whose current depressive episode is at least three months in duration at the Baseline Visit.

Exclusion Criteria:

• Males

• Patients with treatment resistance to other antidepressants